Expert Interview
A Second Look: Examining the phase 2 result of Vaxcyte’s VAX-24 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Ticker(s): PCVX- Board Certified Internal Medicine
- Hospitalist since 2007
- Telemedicine Physician since 2011
- Sees approximately 15 patients per month with pneumococcal disease
- Reviewed the most recent topline data for the PCVX 24 valent vaccine
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
